The anti‐oestrogen drug tamoxifen is an elongation inhibitor of eukaryotic protein biosynthesis
- 20 October 1986
- journal article
- Published by Wiley in FEBS Letters
- Vol. 207 (1), 121-126
- https://doi.org/10.1016/0014-5793(86)80024-2
Abstract
The drug tamoxifen is widely used in the chemotherapy of breast cancer but its action is not explained completely by its anti-oestrogen properties. We now present evidence indicating that it is also a potent inhibitor of eukaryotic protein synthesis as demonstrated in Xenopus oocytes, intact reticulocytes and reticulocyte lysates. The inhibition affects general protein synthesis, is transient in oocytes and not reversed by oestrogen. The drug appears to act by inhibiting polypeptide chain elongation. This action of tamoxifen is independent of oestrogen receptors and may explain its therapeutic effectiveness in oestrogen-independent tumours.Keywords
This publication has 8 references indexed in Scilit:
- Control of protein synthesis by amino acid supplyFEBS Letters, 1986
- Effects of the Antiestrogens Tamoxifen and Clomiphene on Bone Resorptionin Vitro*Endocrinology, 1986
- The pharmacology and clinical uses of tamoxifenPharmacology & Therapeutics, 1984
- Injection of partially purified estrogen receptor protein from Xenopus liver nuclei into oocytes activates the silent vitellogenin locus.Proceedings of the National Academy of Sciences of the United States of America, 1984
- The biology and physiology of ‘Nolvadex’ (tamoxifen) in the treatment of breast cancerBreast Cancer Research and Treatment, 1982
- Quantitative Film Detection of 3H and 14C in Polyacrylamide Gels by FluorographyEuropean Journal of Biochemistry, 1975
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Nature, 1970
- Modified ribosomes conferring resistance to cycloheximide in mutants of Saccharomyces cerevisiaeJournal of Molecular Biology, 1967